ATHX - Athersys, Inc.
| Previous Close | 1.3900 |
| Open | 1.4000 |
| Bid | 1.3500 x 1300 |
| Ask | 1.5600 x 4000 |
| Day's Range | 1.3500 - 1.4173 |
| 52 Week Range | 1.3500 - 3.0900 |
| Volume | 500,272 |
| Avg. Volume | 581,487 |
| Market Cap | 204.112M |
| Beta (3Y Monthly) | 1.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1800 |
| Earnings Date | May 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.67 |
- GlobeNewswire•4 days ago
Athersys to Host Investor Day in New York City
Athersys, Inc. (ATHX) announced today that the company will host an investor day on Tuesday, May 14, 2019. The investor day will include presentations from the Company’s management team as well as experts in the fields of stroke and ARDS. Dr. David Chiu, MD, FAHA, Medical Director at the Eddy Scurlock Stroke Center at Houston Methodist Hospital will be discussing the MASTERS-2 clinical trial for stroke.
- GlobeNewswire•9 days ago
Athersys to Host First Quarter Financial Results Call
CLEVELAND, April 10, 2019 -- Athersys, Inc. (Nasdaq: ATHX) will release its first quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, May 8,.
- Thomson Reuters StreetEvents•last month
Edited Transcript of ATHX earnings conference call or presentation 14-Mar-19 8:30pm GMT
Q4 2018 Athersys Inc Earnings Call
- Zacks•last month
What Makes Athersys (ATHX) a New Buy Stock
Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Motley Fool•last monthAthersys Inc (ATHX) Q4 2018 Earnings Conference Call Transcript
ATHX earnings call for the period ending December 31, 2019.
- GlobeNewswire•last month
Athersys Announces Financial Results for Fourth Quarter and Full Year 2018
Substantial progress over the year, advancing programs andexpanding collaboration with HEALIOS K.K. Management to host conference call at 4:30 PM EST today CLEVELAND, March.
- ACCESSWIRE•last month
Athersys, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 14, 2019 / Athersys, Inc. (NASDAQ: ATHX ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 14, 2019, 2018 at 4:30 PM ...
- Zacks•last month
Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.
- Simply Wall St.•2 months ago
Is Athersys, Inc.’s (NASDAQ:ATHX) CEO Paid Enough Relative To Peers?
Gil Van Bokkelen has been the CEO of Athersys, Inc. (NASDAQ:ATHX) since 1995. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look atRead More...
- GlobeNewswire•2 months ago
Athersys to Host Year-End 2018 Financial Results Call
CLEVELAND, Feb. 14, 2019 -- Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, March 14, 2019,.
- Zacks•3 months ago
Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study
Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.
- Zacks•3 months ago
Athersys (ATHX) Upgraded to Buy: What Does It Mean for the Stock?
Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- GlobeNewswire•3 months ago
Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem® Cell Therapy for Treatment of Acute Respiratory Distress Syndrome (ARDS)
Athersys, Inc. (ATHX) announced today summary results from its exploratory clinical study of the intravenous administration of MultiStem® cell therapy to treat patients who are suffering from acute respiratory distress syndrome (ARDS). The study results provide further confirmation of tolerability and a favorable safety profile associated with MultiStem treatment. Importantly, MultiStem treatment was associated with lower mortality and a greater number of ventilator-free and intensive care unit (ICU) free days in the first month following diagnosis relative to patients receiving placebo.
- GlobeNewswire•4 months ago
Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem® Therapy for Indications in China
Athersys, Inc. (ATHX) announced today the extension of HEALIOS K.K.’s (Healios) exclusive period to negotiate an option that would allow Healios to obtain a license for the development and commercialization of MultiStem therapy for certain indications in China. Healios has agreed to make a one-time $2.0 million payment in December 2018 for an extension through June 30, 2019. Furthermore, Healios may make an additional payment of $3.0 million to extend the negotiation period for another six months through December 31, 2019.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of ATHX earnings conference call or presentation 6-Nov-18 9:30pm GMT
Q3 2018 Athersys Inc Earnings Call
- Simply Wall St.•5 months ago
Are Athersys Inc’s (NASDAQ:ATHX) Interest Costs Too High?
The direct benefit for Athersys Inc (NASDAQ:ATHX), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off is Read More...
- GlobeNewswire•5 months ago
Athersys Reports Third Quarter 2018 Results
Management to host conference call at 4:30pm EST today CLEVELAND, Nov. 06, 2018 -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the period ended.
- Zacks•6 months ago
Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7%
Audentes Therapeutics (BOLD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
- Zacks•6 months ago
Alnylam Files Clinical Trial Application for ALN-AAT02 in UK
Alnylam Pharmaceuticals (ALNY) submits a Clinical Trial Authorization application in the U.K. to start a phase I/II study on its early stage candidate, ALN-AAT02, for treating alpha-1 liver disease.
- Zacks•7 months ago
Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo
Amgen (AMGN) gains an FDA approval for its sNDA with respect to a once-weekly dosing option of its multiple myeloma drug Kyprolis (70 mg/m2) combined with dexamethasone (Kd).
- ACCESSWIRE•7 months ago
Global Stem Cell Market Expected to Reach $270.5 Billion
HENDERSON, NV / ACCESSWIRE / October 2, 2018 / The global stem cell market is expected to reach US 270.5 Billion by 2025, while increasing at a compound annual growth rate of 13.8% during the period from ...
- Simply Wall St.•7 months ago
Who Are The Major Shareholders Of Athersys Inc (NASDAQ:ATHX)?
A look at the shareholders of Athersys Inc (NASDAQ:ATHX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to seeRead More...
